A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

GSK (NYSE:GSK) reported on Thursday positive ... for multiple myeloma to report positive results. The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus ...

The GSK name and elements of the incumbent orange logo have been retained in the new identity. Stevens says that the decision to retain the orange was partly driven by the fact that “the world of ...

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster ...

However, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...

(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...

Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and our new vaccine to prevent meningitis (MenABCWY).' Sheena Berry, an analyst at Quilter Cheviot, said: 'GSK’s third quarter results for ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... and I'm delighted that we filed Blenrep in Europe, Japan, and the U.S ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster ... five major new product approval opportunities next year.” Blenrep, a treatment for cancer, and asthma medicine Depemokimab ...